BACKGROUND: Lymphocyte differentiation is regulated by coordinated actions of cytokines and signaling pathways. IL-21 activates STAT1, STAT3, and STAT5 and is fundamental for the differentiation of human B cells into memory cells and antibody-secreting cells. While STAT1 is largely nonessential and STAT3 is critical for this process, the role of STAT5 is unknown. OBJECTIVES: This study sought to delineate unique roles of STAT5 in activation and differentiation of human naive and memory B cells. METHODS: STAT activation was assessed by phospho-flow cytometry cell sorting. Differential gene expression was determined by RNA-sequencing and quantitative PCR. The requirement for STAT5B in B-cell and CD4+ T-cell differentiation was assessed using CRISPR-mediated STAT5B deletion from B-cell lines and investigating primary lymphocytes from individuals with germline STAT5B mutations. RESULTS: IL-21 activated STAT5 and strongly induced SOCS3 in human naive, but not memory, B cells. Deletion of STAT5B in B-cell lines diminished IL-21-mediated SOCS3 induction. PBMCs from STAT5B-null individuals contained expanded populations of immunoglobulin class-switched B cells, CD21loTbet+ B cells, and follicular T helper cells. IL-21 induced greater differentiation of STAT5B-deficient B cells into plasmablasts in vitro than B cells from healthy donors, correlating with higher expression levels of transcription factors promoting plasma cell formation. CONCLUSIONS: These findings reveal novel roles for STAT5B in regulating IL-21-induced human B-cell differentiation. This is achieved by inducing SOCS3 to attenuate IL-21 signaling, and BCL6 to repress class switching and plasma cell generation. Thus, STAT5B is critical for restraining IL-21-mediated B-cell differentiation. These findings provide insights into mechanisms underpinning B-cell responses during primary and subsequent antigen encounter and explain autoimmunity and dysfunctional humoral immunity in STAT5B deficiency.

• Klíčová slova
• CD21(lo) B cells, Human B-cell differentiation, IL-21, STAT5B, immune dysregulation, immunoglobulin class switching, inborn errors of immunity, plasma cell generation,
• MeSH
• buněčná diferenciace MeSH
• cytokiny * metabolismus   MeSH
• homeostáza MeSH
• imunoglobulinové izotypy metabolismus   MeSH
• lidé MeSH
• RNA MeSH
• transkripční faktor STAT5 * genetika   metabolismus   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• cytokiny * MeSH
• imunoglobulinové izotypy MeSH
• RNA MeSH
• STAT5B protein, human MeSH Prohlížeč
• transkripční faktor STAT5 * MeSH

Growth hormone (GH) insensitivity syndrome (GHIS) is a rare clinical condition in which production of insulin-like growth factor 1 is blunted and, consequently, postnatal growth impaired. Autosomal-recessive mutations in signal transducer and activator of transcription (STAT5B), the key signal transducer for GH, cause severe GHIS with additional characteristics of immune and, often fatal, pulmonary complications. Here we report dominant-negative, inactivating STAT5B germline mutations in patients with growth failure, eczema, and elevated IgE but without severe immune and pulmonary problems. These STAT5B missense mutants are robustly tyrosine phosphorylated upon stimulation, but are unable to nuclear localize, or fail to bind canonical STAT5B DNA response elements. Importantly, each variant retains the ability to dimerize with wild-type STAT5B, disrupting the normal transcriptional functions of wild-type STAT5B. We conclude that these STAT5B variants exert dominant-negative effects through distinct pathomechanisms, manifesting in milder clinical GHIS with general sparing of the immune system.

• MeSH
• buněčné linie MeSH
• dítě MeSH
• ekzém genetika   MeSH
• genetická predispozice k nemoci genetika   MeSH
• HEK293 buňky MeSH
• imunoglobulin E krev   MeSH
• insulinu podobný růstový faktor I biosyntéza   MeSH
• kojenec MeSH
• Laronův syndrom genetika   MeSH
• lidé MeSH
• lidský růstový hormon metabolismus   MeSH
• missense mutace genetika   MeSH
• mladiství MeSH
• responzivní elementy genetika   MeSH
• transkripční faktor STAT5 genetika   MeSH
• zárodečné mutace genetika   MeSH
• Check Tag
• dítě MeSH
• kojenec MeSH
• lidé MeSH
• mladiství MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Research Support, N.I.H., Extramural MeSH
• Názvy látek
• IGF1 protein, human MeSH Prohlížeč
• imunoglobulin E MeSH
• insulinu podobný růstový faktor I MeSH
• lidský růstový hormon MeSH
• STAT5B protein, human MeSH Prohlížeč
• transkripční faktor STAT5 MeSH

BACKGROUND: Anaplastic large cell lymphoma (ALCL) is an aggressive non-Hodgkin T cell lymphoma commonly driven by NPM-ALK. AP-1 transcription factors, cJUN and JUNb, act as downstream effectors of NPM-ALK and transcriptionally regulate PDGFRβ. Blocking PDGFRβ kinase activity with imatinib effectively reduces tumor burden and prolongs survival, although the downstream molecular mechanisms remain elusive. METHODS AND RESULTS: In a transgenic mouse model that mimics PDGFRβ-driven human ALCL in vivo, we identify PDGFRβ as a driver of aggressive tumor growth. Mechanistically, PDGFRβ induces the pro-survival factor Bcl-xL and the growth-enhancing cytokine IL-10 via STAT5 activation. CRISPR/Cas9 deletion of both STAT5 gene products, STAT5A and STAT5B, results in the significant impairment of cell viability compared to deletion of STAT5A, STAT5B or STAT3 alone. Moreover, combined blockade of STAT3/5 activity with a selective SH2 domain inhibitor, AC-4-130, effectively obstructs tumor development in vivo. CONCLUSIONS: We therefore propose PDGFRβ as a novel biomarker and introduce PDGFRβ-STAT3/5 signaling as an important axis in aggressive ALCL. Furthermore, we suggest that inhibition of PDGFRβ or STAT3/5 improve existing therapies for both previously untreated and relapsed/refractory ALK+ ALCL patients.

• Klíčová slova
• ALCL, Apoptosis, NPM-ALK, PDGFRβ, STAT3, STAT5A, STAT5B,
• MeSH
• anaplastická lymfomová kináza MeSH
• anaplastický velkobuněčný lymfom * genetika   patologie   MeSH
• fosforylace MeSH
• karcinogeneze metabolismus   MeSH
• lidé MeSH
• myši MeSH
• nádorové buněčné linie MeSH
• růstový faktor odvozený z trombocytů - receptor beta * metabolismus   farmakologie   MeSH
• signální transdukce MeSH
• transkripční faktor STAT3 * metabolismus   MeSH
• transkripční faktor STAT5 * genetika   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• anaplastická lymfomová kináza MeSH
• růstový faktor odvozený z trombocytů - receptor beta * MeSH
• STAT3 protein, human MeSH Prohlížeč
• transkripční faktor STAT3 * MeSH
• transkripční faktor STAT5 * MeSH

Recurrent gain-of-function mutations in the transcription factors STAT5A and much more in STAT5B were found in hematopoietic malignancies with the highest proportion in mature T- and natural killer-cell neoplasms (peripheral T-cell lymphoma, PTCL). No targeted therapy exists for these heterogeneous and often aggressive diseases. Given the shortage of models for PTCL, we mimicked graded STAT5A or STAT5B activity by expressing hyperactive Stat5a or STAT5B variants at low or high levels in the hematopoietic system of transgenic mice. Only mice with high activity levels developed a lethal disease resembling human PTCL. Neoplasia displayed massive expansion of CD8+ T cells and destructive organ infiltration. T cells were cytokine-hypersensitive with activated memory CD8+ T-lymphocyte characteristics. Histopathology and mRNA expression profiles revealed close correlation with distinct subtypes of PTCL. Pronounced STAT5 expression and activity in samples from patients with different subsets underline the relevance of JAK/STAT as a therapeutic target. JAK inhibitors or a selective STAT5 SH2 domain inhibitor induced cell death and ruxolitinib blocked T-cell neoplasia in vivo We conclude that enhanced STAT5A or STAT5B action both drive PTCL development, defining both STAT5 molecules as targets for therapeutic intervention.

• MeSH
• CD8-pozitivní T-lymfocyty metabolismus   MeSH
• cytokiny MeSH
• leukemie * MeSH
• lidé MeSH
• myši MeSH
• nádorové supresorové proteiny MeSH
• periferní T-buněčný lymfom * genetika   MeSH
• transkripční faktor STAT5 genetika   metabolismus   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• cytokiny MeSH
• nádorové supresorové proteiny MeSH
• STAT5A protein, human MeSH Prohlížeč
• transkripční faktor STAT5 MeSH

C-terminal Src kinase (CSK) is a major negative regulator of Src family tyrosine kinases (SFKs) that play critical roles in immunoreceptor signaling. CSK is brought in contiguity to the plasma membrane-bound SFKs via binding to transmembrane adaptor PAG, also known as CSK-binding protein. The recent finding that PAG can function as a positive regulator of the high-affinity IgE receptor (FcεRI)-mediated mast cell signaling suggested that PAG and CSK have some non-overlapping regulatory functions in mast cell activation. To determine the regulatory roles of CSK in FcεRI signaling, we derived bone marrow-derived mast cells (BMMCs) with reduced or enhanced expression of CSK from wild-type (WT) or PAG knockout (KO) mice and analyzed their FcεRI-mediated activation events. We found that in contrast to PAG-KO cells, antigen-activated BMMCs with CSK knockdown (KD) exhibited significantly higher degranulation, calcium response, and tyrosine phosphorylation of FcεRI, SYK, and phospholipase C. Interestingly, FcεRI-mediated events in BMMCs with PAG-KO were restored upon CSK silencing. BMMCs with CSK-KD/PAG-KO resembled BMMCs with CSK-KD alone. Unexpectedly, cells with CSK-KD showed reduced kinase activity of LYN and decreased phosphorylation of transcription factor STAT5. This was accompanied by impaired production of proinflammatory cytokines and chemokines in antigen-activated cells. In line with this, BMMCs with CSK-KD exhibited enhanced phosphorylation of protein phosphatase SHP-1, which provides a negative feedback loop for regulating phosphorylation of STAT5 and LYN kinase activity. Furthermore, we found that in WT BMMCs SHP-1 forms complexes containing LYN, CSK, and STAT5. Altogether, our data demonstrate that in FcεRI-activated mast cells CSK is a negative regulator of degranulation and chemotaxis, but a positive regulator of adhesion to fibronectin and production of proinflammatory cytokines. Some of these pathways are not dependent on the presence of PAG.

• Klíčová slova
• C-terminal Src kinase, LYN, SHP-1, STAT5, cytokines, degranulation, mast cell, phosphoprotein associated with glycosphingolipid-enriched microdomains,
• MeSH
• analýza rozptylu MeSH
• buňky kostní dřeně fyziologie   MeSH
• C-terminální Src kinasa MeSH
• cytokiny metabolismus   MeSH
• degranulace buněk MeSH
• fibronektiny metabolismus   MeSH
• fosfoproteiny metabolismus   MeSH
• fosforylace MeSH
• genetické vektory MeSH
• HEK293 buňky MeSH
• lidé MeSH
• mastocyty fyziologie   MeSH
• membránové proteiny metabolismus   MeSH
• mezibuněčné signální peptidy a proteiny MeSH
• myši inbrední C57BL MeSH
• myši knockoutované MeSH
• myši MeSH
• receptory IgE metabolismus   MeSH
• signální transdukce imunologie   MeSH
• skupina kinas odvozených od src-genu metabolismus   fyziologie   MeSH
• transkripční faktor STAT5 metabolismus   MeSH
• tyrosin metabolismus   MeSH
• tyrosinfosfatasa nereceptorového typu 6 metabolismus   MeSH
• vápník metabolismus   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• C-terminální Src kinasa MeSH
• CSK protein, human MeSH Prohlížeč
• cytokiny MeSH
• fibronektiny MeSH
• fosfoproteiny MeSH
• lyn protein-tyrosine kinase MeSH Prohlížeč
• membránové proteiny MeSH
• mezibuněčné signální peptidy a proteiny MeSH
• Pag protein, mouse MeSH Prohlížeč
• Pag1 protein, mouse MeSH Prohlížeč
• Ptpn6 protein, mouse MeSH Prohlížeč
• receptory IgE MeSH
• skupina kinas odvozených od src-genu MeSH
• transkripční faktor STAT5 MeSH
• tyrosin MeSH
• tyrosinfosfatasa nereceptorového typu 6 MeSH
• vápník MeSH

The role of somatic JAK2 mutations in clonal myeloproliferative neoplasms (MPNs) is well established. Recently, germ line JAK2 mutations were associated with polyclonal hereditary thrombocytosis and triple-negative MPNs. We studied a patient who inherited 2 heterozygous JAK2 mutations, E846D from the mother and R1063H from the father, and exhibited erythrocytosis and megakaryocytic atypia but normal platelet number. Culture of erythroid progenitors from the patient and his parents revealed hypersensitivity to erythropoietin (EPO). Using cellular models, we show that both E846D and R1063H variants lead to constitutive signaling (albeit much weaker than JAK2 V617F), and both weakly hyperactivate JAK2/STAT5 signaling only in the specific context of the EPO receptor (EPOR). JAK2 E846D exhibited slightly stronger effects than JAK2 R1063H and caused prolonged EPO-induced phosphorylation of JAK2/STAT5 via EPOR. We propose that JAK2 E846D predominantly contributes to erythrocytosis, but is not sufficient for the full pathological phenotype to develop. JAK2 R1063H, with very weak effect on JAK2/STAT5 signaling, is necessary to augment JAK2 activity caused by E846D above a threshold level leading to erythrocytosis with megakaryocyte abnormalities. Both mutations were detected in the germ line of rare polycythemia vera, as well as certain leukemia patients, suggesting that they might predispose to hematological malignancy.

• MeSH
• dospělí MeSH
• fosforylace MeSH
• Janus kinasa 2 genetika   MeSH
• lidé středního věku MeSH
• lidé MeSH
• megakaryocyty metabolismus   patologie   MeSH
• mladiství MeSH
• mladý dospělý MeSH
• polycytemie vrozené   genetika   MeSH
• receptory erythropoetinu genetika   metabolismus   MeSH
• signální transdukce MeSH
• transkripční faktor STAT5 genetika   metabolismus   MeSH
• zárodečné mutace genetika   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH
• práce podpořená grantem MeSH
• Názvy látek
• JAK2 protein, human MeSH Prohlížeč
• Janus kinasa 2 MeSH
• receptory erythropoetinu MeSH
• transkripční faktor STAT5 MeSH

BACKGROUND: Congenital skeletal abnormalities are a heterogeneous group of diseases most commonly associated with small or disproportionate growth, cranial and facial dysmorphisms, delayed bone maturation, etc. Nonetheless, no detailed genotype-phenotype correlation in patients with specific genetic variants is readily available. Ergo, this study focuses on the analysis of patient phenotypes with candidate variants in genes involved in bone growth as detected by molecular genetic analysis. METHODS: In this study we used molecular genetic methods to analyse the ACAN, COL2A1, FGFR3, IGFALS, IGF1, IGF1R, GHR, NPR2, STAT5B and SHOX genes in 128 Czech children with suspected congenital skeletal abnormalities. Pathogenic variants and variants of unclear clinical significance were identified and we compared their frequency in this study cohort to the European non-Finnish population. Furthermore, a prediction tool was utilised to determine their possible impact on the final protein. All clinical patient data was obtained during pre-test genetic counselling. RESULTS: Pathogenic variants were identified in the FGFR3, GHR, COL2A1 and SHOX genes in a total of six patients. Furthermore, we identified 23 variants with unclear clinical significance and high allelic frequency in this cohort of patients with skeletal abnormalities. Five of them have not yet been reported in the scientific literature. CONCLUSION: Congenital skeletal abnormalities may lead to a number of musculoskeletal, neurological, cardiovascular problems. Knowledge of specific pathogenic variants may help us in therapeutic procedures.

• Klíčová slova
• Genomic variants, Sequencing, Short stature, Skeleton,
• MeSH
• dítě MeSH
• frekvence genu genetika   MeSH
• genetické asociační studie MeSH
• kostra * metabolismus   MeSH
• lidé MeSH
• poruchy růstu * epidemiologie   genetika   metabolismus   MeSH
• protein SHOX genetika   MeSH
• Check Tag
• dítě MeSH
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• Geografické názvy
• Česká republika MeSH
• Názvy látek
• protein SHOX MeSH
• SHOX protein, human MeSH Prohlížeč

UNLABELLED: Mutations of the truncated cytoplasmic domain of human erythropoietin receptor (EPOR) result in gain-of-function of erythropoietin (EPO) signaling and a dominantly inherited polycythemia, primary familial and congenital polycythemia (PFCP). We interrogated the unexplained transient absence of perinatal polycythemia observed in PFCP patients using an animal model of PFCP to examine its erythropoiesis during embryonic, perinatal, and early postnatal periods. In this model, we replaced the murine EpoR gene (mEpoR) with the wild-type human EPOR (wtHEPOR) or mutant human EPOR gene (mtHEPOR) and previously reported that the gain-of-function mtHEPOR mice become polycythemic at 3~6 weeks of age, but not at birth, similar to the phenotype of PFCP patients. In contrast, wtHEPOR mice had sustained anemia. We report that the mtHEPOR fetuses are polycythemic, but their polycythemia is abrogated in the perinatal period and reappears again at 3 weeks after birth. mtHEPOR fetuses have a delayed switch from primitive to definitive erythropoiesis, augmented erythropoietin signaling, and prolonged Stat5 phosphorylation while the wtHEPOR fetuses are anemic. Our study demonstrates the in vivo effect of excessive EPO/EPOR signaling on developmental erythropoiesis switch and describes that fetal polycythemia in this PFCP model is followed by transient correction of polycythemia in perinatal life associated with low Epo levels and increased exposure of erythrocytes' phosphatidylserine. We suggest that neocytolysis contributes to the observed perinatal correction of polycythemia in mtHEPOR newborns as embryos leaving the hypoxic uterus are exposed to normoxia at birth. KEY MESSAGE: Human gain-of-function EPOR (mtHEPOR) causes fetal polycythemia in knock-in mice. Wild-type human EPOR causes fetal anemia in knock-in mouse model. mtHEPOR mice have delayed switch from primitive to definitive erythropoiesis. Polycythemia of mtHEPOR mice is transiently corrected in perinatal life. mtHEPOR newborns have low Epo and increased exposure of erythrocytes' phosphatidylserine.

• Klíčová slova
• Augmented Stat5 signaling, Fetal polycythemia, Human EPOR mutation, Neocytolysis, Prolonged primitive erythropoiesis,
• MeSH
• aktivační mutace * MeSH
• anemie krev   genetika   metabolismus   MeSH
• erythropoetin metabolismus   MeSH
• erytrocyty metabolismus   MeSH
• erytroidní prekurzorové buňky metabolismus   MeSH
• erytropoéza genetika   MeSH
• fosforylace MeSH
• genotyp MeSH
• hematokrit MeSH
• hemoglobiny genetika   MeSH
• lidé MeSH
• myši transgenní MeSH
• myši MeSH
• polycytemie krev   genetika   metabolismus   MeSH
• receptory erythropoetinu genetika   metabolismus   MeSH
• regulace genové exprese * MeSH
• signální transdukce MeSH
• transkripční faktor STAT5 metabolismus   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Research Support, U.S. Gov't, Non-P.H.S. MeSH
• Názvy látek
• erythropoetin MeSH
• hemoglobiny MeSH
• receptory erythropoetinu MeSH
• transkripční faktor STAT5 MeSH

• MeSH
• autoimunitní hemolytická anemie farmakoterapie   genetika   MeSH
• beta-globiny genetika   izolace a purifikace   MeSH
• bronchiální astma genetika   MeSH
• buněčná diferenciace MeSH
• chelátory železa terapeutické užití   MeSH
• dítě MeSH
• erythropoetin metabolismus   MeSH
• erytrocyty fyziologie   MeSH
• erytropoéza genetika   MeSH
• kultivované buňky MeSH
• lidé MeSH
• proliferace buněk MeSH
• receptory erythropoetinu metabolismus   MeSH
• regulace genové exprese MeSH
• sekvenování exomu MeSH
• signální transdukce MeSH
• stupeň závažnosti nemoci MeSH
• transkripční faktor STAT3 genetika   MeSH
• transkripční faktor STAT5 metabolismus   MeSH
• zárodečné mutace genetika   MeSH
• Check Tag
• dítě MeSH
• lidé MeSH
• Publikační typ
• dopisy MeSH
• práce podpořená grantem MeSH
• Názvy látek
• beta-globiny MeSH
• chelátory železa MeSH
• erythropoetin MeSH
• receptory erythropoetinu MeSH
• transkripční faktor STAT3 MeSH
• transkripční faktor STAT5 MeSH

BACKGROUND & AIMS: Patients with decompensated cirrhosis suffer from recurrent infections and inadequate responses to prophylactic vaccinations. However, many patients present with hypergammaglobulinemia (HGG), indicating a sustained ability to generate antibody responses. As follicular T helper (Tfh) cells are central facilitators of humoral immunity, we hypothesized that Tfh cell responses may be altered in advanced liver disease and we aimed to identify the mechanisms underlying any such alterations. METHODS: Tfh, regulatory T (Treg) cells, B cells, circulating cytokines and immunoglobulins were analyzed in cohorts of patients with compensated (n = 37) and decompensated cirrhosis (n = 82) and in non-cirrhotic controls (n = 45). Intrahepatic T cells were analyzed in 8 decompensated patients. The influence of IL-2 on Tfh cell function was evaluated in vitro, including Tfh cell cloning and T cell-B cell co-cultures with clones and primary tonsil-derived Tfh cells. RESULTS: Tfh cell frequencies were reduced in patients with decompensated cirrhosis, with phenotypic signatures indicative of increased IL-2 signaling. Soluble IL-2 receptor (sCD25) was elevated in these patients and CD4 T cells were more responsive to IL-2 signaling, as characterized by STAT5 phosphorylation. IL-2 exposure in vitro diminished the Tfh phenotype and resulted in impaired Tfh helper function in co-culture experiments with naïve B cells. Tfh cells were barely detectable in cirrhotic livers. IL-2 signatures on Tfh cells in decompensated patients correlated with immunoglobulin levels, which were found to be associated with improved survival. CONCLUSIONS: Tfh cell impairment represents a previously underestimated feature of cirrhosis-associated immune dysfunction that is driven by IL-2. The presence of HGG in decompensated patients predicts an intact Tfh cell compartment and is associated with a favorable outcome. LAY SUMMARY: Patients with advanced cirrhosis often fail to generate protective immunity after prophylactic vaccinations and suffer from recurring infections that are associated with high mortality. Follicular T helper (Tfh) cells are specialized CD4 T cells that enable the emergence of antibody responses against microbial pathogens. This report demonstrates that Tfh cells are impaired in patients with advanced cirrhosis due to interleukin-2 signaling, a cytokine that is known to impair the generation of Tfh cells.

• Klíčová slova
• CD4 T cells, Cellular immunity, Hepatic decompensation, Immunosuppression,
• MeSH
• B-lymfocyty imunologie   MeSH
• dospělí MeSH
• folikulární pomocné T-buňky imunologie   MeSH
• hypergamaglobulinemie komplikace   MeSH
• imunoglobulin G krev   MeSH
• interleukin-2 krev   MeSH
• jaterní cirhóza krev   komplikace   imunologie   MeSH
• kohortové studie MeSH
• kokultivační techniky MeSH
• kultivované buňky MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádorové supresorové proteiny metabolismus   MeSH
• prognóza MeSH
• průřezové studie MeSH
• regulační T-lymfocyty imunologie   MeSH
• senioři MeSH
• signální transdukce imunologie   MeSH
• transkripční faktor STAT5 metabolismus   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• IL2 protein, human MeSH Prohlížeč
• imunoglobulin G MeSH
• interleukin-2 MeSH
• nádorové supresorové proteiny MeSH
• STAT5A protein, human MeSH Prohlížeč
• transkripční faktor STAT5 MeSH